U.S. flag

An official website of the United States government

Display Settings:

Items per page
You searched 8+ million full text articles

Try this search in 34+ million citations and abstracts

PMC Full-Text Search Results

Items: 8

1.
Fig 2

Fig 2. From: A Double-Blind, Placebo-Controlled Study of Repetitive Transnasal Sphenopalatine Ganglion Blockade With Tx360® as Acute Treatment for Chronic Migraine.

Study flow diagram.

Roger Cady, et al. Headache. 2015 Jan;55(1):101-116.

CitationFull text

2.
Fig 1

Fig 1. From: A Double-Blind, Placebo-Controlled Study of Repetitive Transnasal Sphenopalatine Ganglion Blockade With Tx360® as Acute Treatment for Chronic Migraine.

Sphenopalatine ganglion. Reproduced with permission from Primary Care Network©.

Roger Cady, et al. Headache. 2015 Jan;55(1):101-116.

CitationFull text

3.
Fig 5

Fig 5. From: A Double-Blind, Placebo-Controlled Study of Repetitive Transnasal Sphenopalatine Ganglion Blockade With Tx360® as Acute Treatment for Chronic Migraine.

Average numeric rating scale scores 30 minutes after repetitive sphenopalatine blocks with either bupivacaine or saline.

Roger Cady, et al. Headache. 2015 Jan;55(1):101-116.

CitationFull text

4.
Fig 6

Fig 6. From: A Double-Blind, Placebo-Controlled Study of Repetitive Transnasal Sphenopalatine Ganglion Blockade With Tx360® as Acute Treatment for Chronic Migraine.

Average numeric rating scale scores 24 hours after repetitive sphenopalatine blocks with either bupivacaine or saline.

Roger Cady, et al. Headache. 2015 Jan;55(1):101-116.

CitationFull text

5.
Fig 4

Fig 4. From: A Double-Blind, Placebo-Controlled Study of Repetitive Transnasal Sphenopalatine Ganglion Blockade With Tx360® as Acute Treatment for Chronic Migraine.

Average numeric rating scale scores 15 minutes after repetitive sphenopalatine blocks with either bupivacaine or sham saline.

Roger Cady, et al. Headache. 2015 Jan;55(1):101-116.

CitationFull text

6.
Fig 8

Fig 8. From: A Double-Blind, Placebo-Controlled Study of Repetitive Transnasal Sphenopalatine Ganglion Blockade With Tx360® as Acute Treatment for Chronic Migraine.

Repetitive sphenopalatine blocks with bupivacaine caused a statistically significant decrease in Headache Impact Test-6 scores, P = .005*; bupivacaine n = 25, saline n = 11.

Roger Cady, et al. Headache. 2015 Jan;55(1):101-116.

CitationFull text

7.
Fig 3

Fig 3. From: A Double-Blind, Placebo-Controlled Study of Repetitive Transnasal Sphenopalatine Ganglion Blockade With Tx360® as Acute Treatment for Chronic Migraine.

Treatment with bupivacaine delivered with the Tx360® device reduced average pooled numeric rating scale (NRS) scores compared with those treated with saline. Average NRS scores from all treatments pooled are shown. Between group P values: Before treatment *P = .010; 15 minutes, 30 minutes, and 24 hours posttreatment **P < .001.

Roger Cady, et al. Headache. 2015 Jan;55(1):101-116.

CitationFull text

8.
Fig 7

Fig 7. From: A Double-Blind, Placebo-Controlled Study of Repetitive Transnasal Sphenopalatine Ganglion Blockade With Tx360® as Acute Treatment for Chronic Migraine.

Subjects treated with bupivacaine had a statistically significant greater decrease in pooled numeric rating scale scores from baseline compared to those receiving sham saline. Between group P values: 15 minutes, 30 minutes, 24 hours posttreatment P < .001.

Roger Cady, et al. Headache. 2015 Jan;55(1):101-116.

CitationFull text

Display Settings:

Items per page

Supplemental Content

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
You are here: NCBI > Literature > PubMed Central (PMC)
Support Center